Short answer
HARROW, INC. (HROW) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $71M (up 10.9% year over year) with net income of −$17M.
Q2 2026 key financials · XBRL
- Revenue
- $71M
- +10.9% YoY · +59.9% QoQ
- Net income
- −$17M
- −445.7% YoY · +37.4% QoQ
- Operating margin
- -15.6%
- Gross margin
- 71.3%
- EPS (diluted)
- −$0.46
- −406.7% YoY · +37.8% QoQ
Source: XBRL data from the HARROW, INC. (HROW) Q2 2026 10-Q on SEC EDGAR. USD.
HARROW, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Reimbursement risk: amended and restated risk factor highlights payor step edits, prior authorization, formulary restrictions, and rate reductions
- Regulatory risk: proposed GLOBE and GUARD models could impose international-benchmark rebates on ophthalmology products
- Compliance risk: unsupported or overstated rebate claims may require legal analysis and adversely affect revenues and cash flows
- Operational risk: gross-to-net estimates depend on channel inventory, utilization, payor mix, and claims activity
- Pricing risk: limited control over non-U.S. prices may increase exposure to international-reference pricing policies
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other HARROW, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.